-

Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Catalent Pharma Solutions, Samsung Biologics and Other Key Industry Players - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Biologics Contract Development and Manufacturing Organization Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering.

The global biologics contract development and manufacturing organization (CDMO) market, valued at USD 19.22 billion in 2024, is projected to grow at a compound annual growth rate of 9.21%, reaching USD 42.32 billion by 2033. This expansion is fueled by the increasing demand for targeted therapies to address chronic and rare diseases within an aging global population.

Pharmaceutical and biopharmaceutical companies are leveraging CDMO services to enhance their capacities and access specialized technologies. This trend is further supported by rising investments and a surge in venture capital, strategic collaborations, mergers, and acquisitions across the industry. Major pharmaceutical corporations are focusing on acquisitions to diversify their therapeutic portfolios and bolster biologics pipelines.

The shifting focus of regulatory bodies such as the U.S. FDA and EMA on refining approval pathways for biosimilars, cell therapies, and gene-based treatments is fostering innovation while ensuring patient safety. New harmonized standards are streamlining submissions, reducing delays, and driving market expansion through faster approvals of novel therapies.

Global Biologics CDMO Market Segmentation

This report delivers revenue growth forecasts at global, regional, and country levels from 2021 to 2033 across several sub-segments, divided by product, service, source, workflow, therapeutic area, and region.

Product Outlook (Revenue, USD Million, 2021-2033)

  • Monoclonal antibodies (mAbs)
  • Recombinant proteins & enzymes
  • Vaccines
  • Cell & Gene Therapies
  • Nucleic acid Therapeutics
  • Others

Service Outlook (Revenue, USD Million, 2021-2033)

  • Contract Development
  • Contract Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Logistics & Storage
  • Others

Source Outlook (Revenue, USD Million, 2021-2033)

  • Mammalian
  • Microbial

Workflow Outlook (Revenue, USD Million, 2021-2033)

  • Clinical
  • Commercial

Therapeutic Area Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Neurological Diseases
  • Others

End Use Outlook (Revenue, USD Million, 2021-2033)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic and Research Institutions
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Why You Should Buy This Report

  • Access comprehensive market analysis across major regions and segments.
  • Explore the competitive landscape and key player presence.
  • Identify pivotal trends and drivers shaping the market's future.
  • Leverage actionable recommendations to discover new revenue streams.

Report Deliverables

  • Market intelligence to guide effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Insight into growth opportunities and trends
  • Revenue forecasts for market assessment
  • Analysis of competition strategies and market shares
  • Product innovation listings to stay competitive

Key Attributes

Report Attribute Details
No. of Pages 120
Forecast Period 2024 - 2033
Estimated Market Value (USD) in 2024 $19.22 Billion
Forecasted Market Value (USD) by 2033 $42.32 Billion
Compound Annual Growth Rate 9.2%
Regions Covered Global

The companies profiled in this Biologics Contract Development and Manufacturing Organization market report include:

  • Lonza Group
  • Catalent Pharma Solutions
  • Samsung Biologics
  • WuXi Biologics / WuXi AppTec
  • Thermo Fisher Scientific
  • Fujifilm Diosynth Biotechnologies
  • Boehringer Ingelheim (Biopharma CDMO)
  • Rentschler Biopharma SE
  • AGC Biologics
  • Charles River Laboratories
  • Siegfried Holding
  • Sandoz
  • GenScript Biologics
  • Vetter Pharma
  • IDT Biologika

For more information about this report visit https://www.researchandmarkets.com/r/idjtme

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Computer System Validation (CSV) Training Course: Regulations Impacting Your Systems and Hands-on Practice Writing Validation Documents (Jan 27th - Jan 29th, 2026 & On-Demand) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Computer System Validation (CSV) Training Course (Jan 27th - Jan 29th, 2026)" training has been added to ResearchAndMarkets.com's offering. A course designed to completely immerse you in computer system validation. This course delivers comprehension of the regulations impacting your systems and hands-on practice writing validation documents. You will leave ready to lead efficient, effective, inspection- ready validation projects. Registration Includes: Checklist of...

Understanding Medical Device Regulatory Pathways - 510(k), PMA & Exemptions Webinar - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Understanding Medical Device Regulatory Pathways - 510(k), PMA & Exemptions (January 15, 2026)" training has been added to ResearchAndMarkets.com's offering. This expert-led 3-hour webinar provides a comprehensive introduction to the key regulatory pathways for medical device submissions in the US market. The regulation and control of new or substantially changed medical devices for sale in the US is based on the 510(k), PMA or DeNovo submission process. This w...

Medical Devices: Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) Course: Developing Effective Post Market Surveillance and Complaint Handling Systems Training - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Medical Devices: Developing Effective Post Market Surveillance and Complaint Handling Systems Course (Jan 22nd - Jan 23rd, 2026)" training has been added to ResearchAndMarkets.com's offering. What are U.S. FDA CGMP expectations/requirements for Post Market Surveillance and Complaint Handling? This seminar will examine Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as well as appropriate articles / Annexes of the EU's MDR, which require manu...
Back to Newsroom